We have located links that may give you full text access.
CLINICAL TRIAL
CONTROLLED CLINICAL TRIAL
JOURNAL ARTICLE
Antipsychotic effect of propranolol on chronic schizophrenics: study of a gradual treatment regimen.
Psychopharmacology 1979 January 32
Ten chronic treatment-resistant schizophrenic patients were treated in a single-blind trial for six weeks with propranolol in daily doses increasing up to 3 g in order to evaluate a modified dose regimen of propranolol treatment in these patients. Four of the patients improved significantly and could be released from the hospital, regaining premorbid social and work adjustments. The modified regimen proved safe as long as the dose increment was not more than 80 mg/day. The mean therapeutic level of propranolol was 1600 mg/day, which proved to be a safe dose. Although three patients with hypertensive encephalophaty responded, their response was related not to the maximum dose but to a drastic change in the rate of the dose increase. It seems that on the basis of these results a double-blind comparative study would be worthwhile.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app